ValeurQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMFrais de vente, généraux et administratifs60.8 M52.4 M43.7 M38.9 M51.1 M186.1 MRecherche et développement9.1 M15.1 M12.5 M13.5 M12.1 M53.2 MRésultat d'exploitation-9.5 M49.9 M1.6 M76.5 M-27.9 M100.1 MTotal des produits hors exploitation-18.1 M42.8 M-18.4 M-18.9 M-22.8 M-17.3 MCharges d'intérêts, nettes des intérêts capitalisés14.8 M14.7 M14.7 M15.2 M14.7 M59.3 MRésultat hors exploitation, hors charges d'intérêts-29.6 M-41.6 M-29.4 M-30.4 M-29.4 M-130.8 MRevenus/dépenses exceptionnels-3.3 M69.7 M-3.7 M-3.7 M-8.1 M54.2 MRésultat avant impôts-27.6 M92.7 M-16.8 M57.6 M-50.7 M82.8 MPart des actionnaires dans le résultat——————Impôts3.7 M24.7 M-4.8 M6.4 M3.9 M30.2 MIntérêts ne donnant pas le contrôle / intérêts minoritaires——————Autres produits/charges après impôts-2.6 M11.3 M-2.2 M-400 K-9.1 M-400 KRésultat net avant activités abandonnées-31.3 M68 M-12 M51.2 M-54.6 M52.6 MActivités abandonnées——————Résultat net-31.3 M68 M-12 M51.2 M-54.6 M52.6 MAjustement de dilution——————Dividendes privilégiés——————Résultat net dilué revenant aux actionnaires ordinaires-31.3 M68 M-12 M51.2 M-54.6 M52.6 MBénéfice par action de base (BPA de base)-0.551.25-0.220.96-1.010.98Bénéfice par action dilué (BPA dilué)-0.451.19-0.220.91-0.950.93Nombre moyen d'actions de base en circulation53 M54.4 M54.2 M53.2 M53.5 M215.3 MNombre d'actions en circulation après dilution53 M57.3 M54.2 M56.5 M56.7 M224.7 MEBITDA-44.5 M-65.3 M-84.5 M-22.7 M-139.4 M-311.9 MEBIT-70.1 M-91.3 M-110 M-50.5 M-164.9 M-416.7 MCoût des ventes—88.5 M66.9 M85.9 M84.9 M326.2 MAutres coûts des ventes——————Amortissements (flux de trésorerie)26 M25.4 M23.5 M23.4 M23.5 M95.8 M
Emergent BioSolutions Inc
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid.
During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded.